Beneficial Effects of a Polyphenol Enriched Beverage on Type 2 Diabetes Prevention and on Cardiovascular Risk Profile of Men and Women With Insulin Resistance.

The purpose of this study is to measure the beneficial effects of an optimized berries extracts on diabetes and cardiovascular diseases prevention. Our hypothesis is that including a polyphenol rich berries extract in daily feeding will improve insulin sensitivity, glucose tolerance, pancreatic β-cells function, lipids and inflammatory profile, and oxidative stress markers.

Study Overview

• Status: Completed
• Conditions: Cardiovascular Disease; Diabetes
• Intervention / Treatment: Other: Placebo; Other: Uncontrolled nutritional intervention with a supplemental beverage

Detailed Description

Type 2 diabetes is an up rising disease that makes it a major public health problem. While 221 millions cases were estimated in 2010, the prevalence would be 366 millions in 2030. It is well recognized that regular consumption of fruits and vegetables can lower the incidence of chronic diseases such as cancer, cardiovascular diseases, diabetes and inflammatory diseases. Recently, Drs Desjardins, Abrams and Marette's research team discovered a high amount of a sesquiterpene in berries. This molecule is recognized for its ability to improve glucose tolerance and insulin sensitivity, and to lower pro-inflammatory profile of obese mice. The aim of this study is to determine the effect of a polyphenol rich berries extract mix on insulin sensitivity, glucose tolerance, pancreatic β-cells function, lipids and inflammatory profile, and oxidative stress markers, on human obese subjects that have insulin resistance.

• Study Type: Interventional
• Enrollment (Actual): 60
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Canada
  • Quebec, Canada, G1V 0A6
    • Institute of Nutraceuticals and Functional Foods (INAF), Laval University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• 40-65 year old
• non-smoking
• overweight (BMI>27)
• insulin resistant (fasting insulin >90pmol/L, with fasting glycemia < 7,0 mmol/L and < 11,1 mmol/L after a 120-min oral glucose tolerance test)

Exclusion Criteria:

• diabetes
• chronic diseases
• taking drugs that could affect glucose or lipids metabolism
• major surgery 3 months prior to the study
• weight variation of ±10% 6 months prior to the study
• strawberry or cranberry allergy
• consumption of berries rich in polyphenol and/or wine more then 3 times per week

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Phenol; Men and women who are assigned to a 6 weeks experimental period where they consume the rich polyphenol berries extract mix.	Other: Uncontrolled nutritional intervention with a supplemental beverage; Men and women are assigned to an uncontrolled nutritional intervention where they have to consume every day one of the beverage. Half of the subjects consume the experimental beverage containing polyphenols from berries extracts, the other half consume a placebo beverage without polyphenols. The polyphenol containing beverage daily supply 1,84 g of a strawberry and cranberry extract. This amount give the equivalent of 333 mg of polyphenols, thus corresponding to a daily consumption of one cup of berries. The placebo beverage is also a fruit taste beverage, but without polyphenols. Both beverage are isocaloric, with same appearance and taste. A 2 weeks stabilisation period precede the 6 weeks experimental period. During these two periods, subjects are advise to maintain their habitual caloric intake and their habitual activity level, and to avoid consumption of particular food with a high polyphenol content.
Placebo Comparator: Control; Men and women who are assigned to a 6 weeks experimental period where they consume a placebo.	Other: Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in cardiometabolic statute from baseline to the end of intervention.	glucose and insulin concentrations during a 120-min euglycemic-hyperinsulinemic clamp, glucose and insulin concentrations during a 120-min oral glucose tolerance test, insulin sensitivity, c-peptide, C-reactive protein (hs-CRP), interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha) and plasminogen activator inhibitor-1 (PAI-1) levels, triglycerides, total cholesterol, very low density lipoprotein cholesterol (cVLDL), low density lipoprotein cholesterol (cLDL), high density lipoprotein cholesterol (cHDL), apolipoprotein A-1 and B, oxidized-LDL, glucose disposition rate (GDR), insulin sensitivity measure (MI), beta-cells function	At baseline (at the beginning of the intervention), and at the end of the intervention (6 weeks)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in nutritional variables from baseline to the end of the intervention.	Food frequency questionnaire	At baseline, and at the end of the intervention period (6 weeks)
Change in physical activity habits from baseline to the end of the intervention.	Physical activity habits questionnaire	) At baseline, and at the end of the intervention period (6 weeks)
Change in anthropometric measurements from baseline to the end of the intervention.	anthropometric measurements (body mass index, waist and hip circumferences)	At baseline, and at the end of the intervention period (6 weeks)

Collaborators and Investigators

• Sponsor: Laval University
• Collaborators: Institute of Nutraceuticals and Functional Foods; Consortium de recherche et innovations en bioprocédés industriels au Québec (CRIBIQ)

Study record dates

Study Major Dates

• Study Start: March 1, 2012
• Primary Completion (Actual): September 1, 2014
• Study Completion (Actual): August 1, 2015

Study Registration Dates

• First Submitted: October 2, 2012
• First Submitted That Met QC Criteria: January 9, 2013
• First Posted (Estimate): January 11, 2013

Study Record Updates

• Last Update Posted (Estimate): September 2, 2015
• Last Update Submitted That Met QC Criteria: September 1, 2015
• Last Verified: September 1, 2015

More Information

Terms related to this study

• Keywords: insulin sensitivity,; glucose tolerance,; inflammatory markers,; lipid profile,; oxidative stress,; pancreatic β-cell function
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Hyperinsulinism; Cardiovascular Diseases; Diabetes Mellitus; Insulin Resistance
• Other Study ID Numbers: PHENOL-C11-12-155